“The U.S. FDA Fast Track designations for our potential first-in-class PARG inhibitor, IDE161, in both BRCA1/2-mutant breast and ovarian cancers reflect the potential for IDE161 to address the significant unmet medical need in these indications,” said Dr. Darrin Beaupre, Chief Medical Officer at IDEAYA Biosciences. “We are excited that IDE161 has been granted Fast Track status in two separate indications, and we look forward to providing further program updates for IDE161 in the fourth quarter of this year,” continued Dr. Beaupre.
